Cost Effectiveness
Conditions
Brief summary
Use of erector spina plane (ESP) block for postoperative analgesia is continuously increasing. However, few studies have investigated intraoperative effects of ESP block. The investigators aim to study the effects of ESP block in terms of cost-effectiveness, consumption of inhalation agents and opioids in perioperative and postoperative period.
Detailed description
Erector spina plane (ESP) block has analgesic efficiency and its popularity is growing steadily. ESP block forms a sensorial block by local anesthetic infiltration between the musculus erector spina and facia. ESP block given to participants undergoing laparoscopic cholecystectomy for postoperative opioid analgesia resulted in a decrease of postoperative pain scores in the first 24 h. Due to increases in health expenditure, cost control is becoming more and more important. Cost-effective studies are important in healthcare economics. Inhaled anesthetics used in anesthesia departments account for about 20% of total anesthetic agents. Local anesthetic agents decrease the minimum alveolar concentration (MAC) value of inhaled agents. And also in perioperative and post operative period, the anesthetic management often need to be supported with opioid drugs. The investigators think that ESP block has analgesic effects and decreases the consumption of inhalation agents. The investigators aim to investigate the cost-effectiveness of ESP block in anesthetic applications in laparoscopic procedures.
Interventions
OTHERerector spina plane block, cost analysis
in preopererative period, ESP block is going to utilise for postoperative analgesia for patients who undergo laparoscopic procedure and cost analysis will make after the end of 24 hour of operation
Sponsors
Kırıkkale University
Study design
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
SCREENING
Masking
DOUBLE (Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
1. American Society of Anesthesiologist (ASA) physical status I-II, 2. ages 18-75 years, 3. undergoing laparoscopic cholecystectomy
Exclusion criteria
1. Patients with cardiac, endocrinological, neurological diseases, 2. patients with coagulation disorders 3. allergy to local anesthetics 4. Operations that started as laparoscopy but transitioned to open surgery for a surgical reason
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| the formula of consumption of inhaled agent | 30 minute after the operation | the formula which includes fresh gas flow, valume of inhaled agent vapor, sevoflurane concentration |
Countries
Turkey (Türkiye)
Outcome results
None listed